Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05DZR
|
|||
| Former ID |
DNCL002786
|
|||
| Drug Name |
Elotuzumab
|
|||
| Synonyms |
BMS-901608
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Approved | [1], [2], [3] | |
| Company |
Bristol-Myers Squibb
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | SLAM family member 7 SLAMF7 (CS1) | Target Info | . | [4], [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8361). | |||
| REF 2 | ClinicalTrials.gov (NCT01335399) Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma. U.S. National Institutesof Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228. | |||
| REF 5 | Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009 Sep;8(9):2616-24. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.